T
Troy Z. Horvat
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 12
Citations - 1207
Troy Z. Horvat is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Venetoclax. The author has an hindex of 8, co-authored 12 publications receiving 963 citations.
Papers
More filters
Journal ArticleDOI
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat,Nelly G. Adel,Thu-Oanh Dang,Parisa Momtaz,Michael A. Postow,Margaret K. Callahan,Richard D. Carvajal,Mark A. Dickson,Sandra P. D'Angelo,Kaitlin M. Woo,Katherine S. Panageas,Jedd D. Wolchok,Paul B. Chapman +12 more
TL;DR: In the experience, approximately one-third of ipilimumab-treated patients required systemic corticosteroids, and almost one- third of those required further immune suppression with anti-TNFα therapy, which does not affect OS or TTF.
Journal ArticleDOI
Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
TL;DR: The treatment landscape in oncology is quickly evolving with the advent of ICIs and treatment recommendations for the management of immune-related adverse events (irAEs), assessed response criteria, and calculated the clinical utility of leading tumor profiling options are calculated.
Journal ArticleDOI
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl,Maximilian Stahl,Kamal Menghrajani,Kamal Menghrajani,Andriy Derkach,Alexander Chan,Wenbin Xiao,Jacob L. Glass,Jacob L. Glass,Amber C. King,Anthony F. Daniyan,Anthony F. Daniyan,Christopher Famulare,Christopher Famulare,Bernadette M. Cuello,Troy Z. Horvat,Omar Abdel-Wahab,Ross L. Levine,Aaron D. Viny,Eytan M. Stein,Eytan M. Stein,Sheng F. Cai,Sheng F. Cai,Mikhail Roshal,Martin S. Tallman,Martin S. Tallman,Aaron D. Goldberg,Aaron D. Goldberg +27 more
TL;DR: Azacitidine + venetoclax, decitabine+ venetocaine, and low-dose cytarabine + Venetocax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML).
Journal ArticleDOI
Blinatumomab A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia
TL;DR: Binatumomab is a novel BiTE therapeutic monoclonal antibody that has shown promising results in patients with relapsed or refractory ALL or those achieving a CR with persistent MRD, and Phase III clinical trials should define the optimal place in therapy of blinumomab.
Journal ArticleDOI
Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80
Claire F. Friedman,Troy Z. Horvat,Janna Minehart,Katherine S. Panageas,Margaret K. Callahan,Paul B. Chapman,Parisa Momtaz,Michael A. Postow,Alexander N. Shoushtari,Jedd D. Wolchok,Stuart M. Lichtman +10 more
TL;DR: The efficacy and safety of these agents in this pt population are reported and mel pts aged 80+.